JERSEY CITY, N.J., March 9, 2025 /PRNewswire/ -- Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and only biosimilar designated ...
Celltrion said on the 25th that Omlyclo (OMLYCLO), a treatment for chronic spontaneous urticaria launched in Europe in Sep., has been released in major countries, including Germany, Spain, the United ...
INCHEON, South Korea, Dec. 1, 2025 /PRNewswire/ -- Celltrion, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO® (omalizumab-igec), the first ...
TORONTO--(BUSINESS WIRE)--Celltrion today announced that Health Canada has approved Omlyclo ™, a biosimilar referencing Xolair ®. Omlyclo ™ is approved for the treatment of adults and adolescents with ...
Celltrion’s Omlyclo™, the first and only omalizumab biosimilar in Europe, will be commercially available starting in Norway, with subsequent rollouts in European countries Results from the global ...
The European Commission (EC) has approved Celltrion’s Omlyclo (CT-P39), an omalizumab biosimilar referencing Novartis and Genentech’s Xolair, for a range of immunological conditions. Omlyclo, which ...
Celltrion announced on December 24 that it has received additional approval from the Ministry of Food and Drug Safety for the autoinjector (AI) formulation of 'OMLYCLO' (ingredient: omalizumab), a ...
Celltrion said on the 4th that OMLYCLO, which treats asthma and urticaria, is expanding its market in Spain. OMLYCLO is a biosimilar of XOLAIR developed by Swiss drugmaker Novartis. Celltrion's ...
Korean biosimilar giant Celltrion announced Thursday that its anti-IgE antibody biosimilar Omlyclo has been approved in Europe, after a series of clinical trials with the reference product Novartis' ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results